Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Ascendis Pharma A (ASND) over the last 12 years, with Q4 2025 value amounting to -$249.1 million.

  • Ascendis Pharma A's Operating Expenses fell 70391.18% to -$249.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$59.3 million, marking a year-over-year decrease of 14530.65%. This contributed to the annual value of -$860.6 million for FY2025, which is 267686.36% down from last year.
  • As of Q4 2025, Ascendis Pharma A's Operating Expenses stood at -$249.1 million, which was down 70391.18% from -$210.8 million recorded in Q3 2025.
  • Over the past 5 years, Ascendis Pharma A's Operating Expenses peaked at $203.2 million during Q2 2025, and registered a low of -$249.1 million during Q4 2025.
  • In the last 5 years, Ascendis Pharma A's Operating Expenses had a median value of $148.0 million in 2022 and averaged $61.0 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first surged by 28164.64% in 2021, then crashed by 70391.18% in 2025.
  • Ascendis Pharma A's Operating Expenses (Quarter) stood at -$132.5 million in 2021, then grew by 26.52% to -$97.4 million in 2022, then skyrocketed by 37.74% to -$60.6 million in 2023, then skyrocketed by 48.9% to -$31.0 million in 2024, then plummeted by 703.91% to -$249.1 million in 2025.
  • Its Operating Expenses stands at -$249.1 million for Q4 2025, versus -$210.8 million for Q3 2025 and $203.2 million for Q2 2025.